NEW YORK, NY / ACCESSWIRE / September 27, 2019 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Abiomed, Inc. (NASDAQGS:ABMD)
Class Period: January 31, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 7, 2019

The lawsuit alleges that throughout the class period, Abiomed, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Abiomed's revenue growth was in decline; (ii) the Company did not have a sufficient plan in place to stem its declining revenue growth; (iii) the Company was unlikely to restore its revenue growth over the next several fiscal quarters; (iv) consequently, Abiomed was reasonably likely to revise its full-year 2020 guidance in a way that would fall short of the Company's prior projections and market expectations; and (v) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in ABMD: http://www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?id=3742&from=1

Valaris plc (NYSE:VAL)
Class Period: April 11, 2019 to July 31, 2019
Lead Plaintiff Deadline: October 21, 2019

The lawsuit alleges that Valaris plc made materially false and/or misleading statements and/or failed to disclose that: (i) the Company was plagued by a weak ultra-deepwater segment, massive cash usage, and significant negative cash flow; (ii) the foregoing was reasonably likely to have a material negative impact on the Company's second quarter 2019 results; (iii) the merger leading to Valaris's establishment could not deliver on its touted benefits; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in VAL: http://www.kleinstocklaw.com/pslra-1/valaris-plc-loss-submission-form?id=3742&from=1

Textron Inc. (NYSE:TXT)
Class Period: January 31, 2018 to October 17, 2018
Lead Plaintiff Deadline: October 21, 2019

The complaint alleges that throughout the class period Textron Inc. made materially false and/or misleading statements and/or failed to disclose that: (1) end market sales of Arctic Cat products were slowing, resulting in a massive glut of old Arctic Cat inventory on dealers' floors; (2) in order to clear out this old inventory, the Company provided significant price discounts, which negatively impacted Textron's earnings; and (3) as a result, Textron's positive statements about Arctic Cat's business, operations, and prospects lacked a reasonable basis.

Learn about your recoverable losses in TXT: http://www.kleinstocklaw.com/pslra-1/textron-inc-loss-submission-form?id=3742&from=1

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
jk@kleinstocklaw.com
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

ReleaseID: 561307

CEDARHURST, NY / ACCESSWIRE / September 27, 2019 / The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are encouraged to contact the firm regarding possible appointment as lead plaintiff and a preliminary estimate of their recoverable losses.

If you wish to choose counsel to represent you and the class, you must apply to be appointed lead plaintiff and be selected by the Court. The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement for the class in the action. The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the respective securities during the class periods. Members of the class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff. No classes have yet been certified in the actions below. Appointment as lead plaintiff is not required to partake in any recovery.

Curaleaf Holdings, Inc. (OTCMKTS:CURLF)

Investors Affected : November 21, 2018 – July 22, 2019

A class action has commenced on behalf of certain shareholders in Curaleaf Holdings, Inc. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) Curaleaf, on its website and social media pages, marketed its CBD products to be used as drugs and dietary supplements, contrary to law; (2) Curaleaf also sold unapproved animal drugs on its website; (3) such conduct would result in a warning letter from the U.S. Food and Drug Administration; and (4) as a result, Defendants' statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times.

Shareholders may find more information at https://kclasslaw.com/securities/curaleaf-holdings-inc-loss-submission-form/?id=3741&from=1

Meredith Corporation (NYSE:MDP)

Investors Affected : January 31, 2018 – September 5, 2019

A class action has commenced on behalf of certain shareholders in Meredith Corporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Time, Inc. acquisition was not as profitable as the Company had claimed; (2) the Company would incur additional costs for strategic investments to improve the Time business; (3) as a result, the Company's earnings would be materially and adversely impacted; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/meredith-corporation-loss-submission-form/?id=3741&from=1

Cadence Bancorporation (NYSE:CADE)

Investors Affected : July 23, 2018 – July 22, 2019

A class action has commenced on behalf of certain shareholders in Cadence Bancorporation. The filed complaint alleges that defendants made materially false and/or misleading statements and/or failed to disclose that: (1) the Company lacked adequate internal controls to assess credit risk; (2) as a result, certain of the Company's loans posed an increased risk of loss; (3) as a result, the Company was reasonably likely to incur significant losses for certain loans; (4) the Company's financial results would suffer a material adverse impact; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Shareholders may find more information at https://kclasslaw.com/securities/cadence-bankcorporation-loss-submission-form/?id=3741&from=1

Kuznicki Law PLLC is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a Company lead to artificial inflation of the Company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Kuznicki Law PLLC
Daniel Kuznicki, Esq.
445 Central Avenue, Suite 344
Cedarhurst, NY 11516
Email: dk@kclasslaw.com
Phone: (347) 696-1134
Cell: (347) 690-0692
Fax: (347) 348-0967

SOURCE: Kuznicki Law PLLC

ReleaseID: 561306

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, reminds investors of the deadline to make a lead plaintiff motion in a securities class action lawsuit filed on behalf of investors who purchased or acquired shares of Just Energy Group Inc. ("Just Energy" or the "Company") (NYSE:JE) between November 9, 2017, and August 19, 2019, inclusive (the "Class Period"). The lawsuit filed in the United States District Court for the Southern District of New York seeks to recover damages for Just Energy investors under the Securities Exchange Act of 1934.

If you purchased Just Energy securities, and/or would like to discuss your legal rights and options please visit JE Shareholder Class Action or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

If you wish to serve as lead plaintiff, you must move the Court no later than September 30, 2019. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Your ability to share in any recovery doesn't require that you serve as lead plaintiff. If you choose to take no action, you may remain an absent class member.

The complaint alleges that throughout the Class Period, Defendants issued a series of false and/or misleading statements and failed to disclose material adverse facts about Just Energy's business, operations, and prospects. Among other things, Defendants misrepresented and failed to disclose to investors: (1) that the Company experienced customer enrollment and nonpayment issues; (2) that, as a result, the Company was reasonably likely to incur an impairment charge to its accounts receivable; (3) that, as a result, the Company lacked adequate internal control over its financial reporting; and (4) that, as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

On July 23, 2019, the Company disclosed that it had "identified customer enrolment [sic] and non-payment issues, primarily in Texas, over the past 12 months" and that, as a result, it expected an impairment charge of CAD $45 to $50 million to its Texas residential accounts receivable.

On this news, the Company's share price fell $0.66 per share, more than 15%, to close at $3.72 per share on July 23, 2019, on unusually heavy trading volume.

Later, on August 4, 2019, the Company revealed collection issues in the U.K. Market that resulted in a $74.1 million impairment.

On this news, shares of Just Energy fell $1.22 per share, or nearly 40% to close at $1.88 per share on August 15, 2019.

Finally, on August 20, 2019, the Company filed its amended annual report for fiscal 2019 with the SEC in which it revealed that its allowance for doubtful accounts had been understated by $111.2 million and that it had a material weakness in its internal controls over financial reporting.

On this news, the Company's share price fell $0.14 per share, or over 10% to close at $1.18 per share on August 21, 2019.

If you purchased Just Energy securities, and/or would like to discuss your legal rights and options please visit https://www.bernlieb.com/cases/just-energy-group-inc-166/apply or contact Matthew E. Guarnero toll free at (877) 779-1414 or MGuarnero@bernlieb.com.

Since 1993, Bernstein Liebhard LLP has recovered over $3.5 billion for its clients. In addition to representing individual investors, the Firm has been retained by some of the largest public and private pension funds in the country to monitor their assets and pursue litigation on their behalf. As a result of its success litigating hundreds of lawsuits and class actions, the Firm has been named to The National Law Journal's "Plaintiffs' Hot List" thirteen times and listed in The Legal 500 for ten consecutive years.

ATTORNEY ADVERTISING. © 2019 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this advertisement in the State of Connecticut is Michael S. Bigin. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Matthew E. Guarnero
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
MGuarnero@bernlieb.com

SOURCE: Bernstein Liebhard LLP

ReleaseID: 561305

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Pluralsight, Inc. (NASDAQGS:PS)

Lawsuit on behalf of: investors who purchased August 2, 2018 – July 31, 2019
Lead Plaintiff Deadline : October 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pluralsight-inc-loss-form?prid=3740&wire=1

According to the filed complaint, the Company failed to disclose that Pluralsight was experiencing substantial delays in hiring and properly training the salesforce necessary to meet its lofty billing projections. In addition, the Company knew at the time of the March 2019 secondary public offering ("SPO") that it was behind schedule onboarding new sales representatives, which was hurting the Company's sales execution and preventing Pluralsight from meeting its high growth projections. Instead of disclosing such facts at the time of the SPO, and to cash-out at inflated prices, Defendants intentionally obscured and omitted this pertinent information from investors.

CVS Health Corporation (NYSE:CVS)

Lawsuit on behalf of: investors who purchased on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for their Aetna shares in connection with CVS's acquisition of Aetna on November 28, 2018.
Lead Plaintiff Deadline : October 15, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cvs-health-corporation-loss-form-2?prid=3740&wire=1

According to the filed complaint, CVS made false and/or misleading statements in connection with its acquisition of Aetna and/or failed to disclose that: (a) by the end of 2017, CVS's financial condition and expected earnings had deteriorated as a result of rising costs and poor results being experienced in the long-term care ("LTC") unit associated with the 2015 acquisition of Omnicare; (b) in 2017, deteriorating conditions and prospects in CVS 's LTC unit prompted CVS to undertake hasty acquisitions of LTC pharmacies to compensate for the declining LTC business and/or mask the expected LTC goodwill impairment ahead of the planned Acquisition; (c) although negative LTC performance factors prompted CVS and the CVS Individual Defendants to make hasty LTC pharmacy acquisitions in 2017, those same negative factors were being overlooked and ignored for purposes of undertaking, disclosing, and reporting the results of LTC goodwill impairment tests throughout 2017, in violation of GAAP; (d) the LTC goodwill being carried on CVS's books as a result of the Omnicare acquisition was being carried at inflated values that would require billions of dollars in impairment charges that would be charged against earnings; and (e) as a result of the foregoing, CVS's true business metrics and financial prospects were not as the Offering Documents represented.

MacroGenics, Inc. (NASDAQGS:MGNX)

Lawsuit on behalf of: investors who purchased February 6, 2019 – June 3, 2019
Lead Plaintiff Deadline : November 12, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/macrogenics-inc-loss-form?prid=3740&wire=1

According to the filed complaint, during the class period, MacroGenics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (a) the Company had conducted the progression-free survival ("PFS") and first interim overall survival ("OS") analyses for the SOPHIA trial by no later than October 10, 2018; (b) the October 2018 PFS analysis showed a 0.9 month improvement in PFS; and (c) the October 2018 OS interim analysis did not produce a statistically significant result and the interim OS Kaplan-Meier curves crossed in several spots (thereby violating the constant hazard assumption) and separated late.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 561304

OTTAWA, ON / ACCESSWIRE / September 27, 2019 / A new voting guide launched today by the Native Women's Association of Canada (NWAC) is designed to encourage Indigenous women and gender-diverse people to get out and vote – thereby ensuring their voices are heard and their perspectives are understood.

The 2019 Voting Guide for Indigenous Women, Two-Spirit and LGBTQQIA Voters, created with support from Elections Canada, is a first for NWAC, and underscores the Association's continuing efforts to keep front and centre the 231 Calls for Justice issued by the National Inquiry for Missing and Murdered Indigenous Women and Girls.

"Just as it is crucial that all federal party leaders honour the Calls for Justice, which are legal imperatives, and pledge their commitment," says NWAC CEO Lynne Groulx, "it is also crucial that Indigenous women, Two-Spirit and LGBTQQIA persons take an active hold on the levers of democracy to shape their future."

Indigenous women are among the fastest-growing populations in Canada – but also greatly under-represented in terms of candidates and number of overall voters in Canadian elections.

The voting guide takes Indigenous women and gender-diverse people through a step-by-step process:

how to register to vote
how to vote if you are a student
how to prove your identity and address
what types of identification items you can use to prove your identity and address
how to vote at the advance polls, by mail or on election day
what to expect at the polling station

Along with a list of the political parties, the guide offers a number of tips on how to decide whom to vote for (for example, think about the issues you care about and look at how the different parties address those issues) and provides a section on how Canada's political system works.

Beyond voting, NWAC is also encouraging Indigenous women and gender-diverse people to consider active participation within or outside the government system. "By running for office, helping with an election campaign, running in a community band election, organizing a community meeting or engaging in social media activism," says Lorraine Whitman, NWAC President, "Indigenous women and gender-diverse peoples can gain confidence in their abilities, as well as enhance awareness around Indigenous issues and priorities."

To ensure a healthy future for all Canadians, including Indigenous women and gender-diverse people, and "with the growing need for real reconciliation, NWAC encourages Indigenous communities to participate in elections at every level of government. The more Indigenous women speak with their voices, the more their voices will be heard," says Ms. Whitman added.

For more information, please contact:

Sherri-Moore-Arbour

NWAC
Director of Public Affairs
613-410-1501
smoore-arbour@nwac.ca

SOURCE: Native Women's Association of Canada

ReleaseID: 561272

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of MacroGenics, Inc. ("MacroGenics" or the "Company") (NASDAQ:MGNX). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether MacroGenics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On May 13, 2019, the American Society of Clinical Oncologists ("ASCO") posted online the abstract of MacroGenics' Phase III SOPHIA study of the Company's margetuximab product, which disclosed that the October 2018 progression-free survival ("PFS") analysis resulted in a 0.9 month improvement in PFS.

On this news, MacroGenics' stock price fell $1.17 per share, or 6.72%, to close at $16.25 per share on May 13, 2019.

Then, on June 4, 2019, during the ASCO annual meeting in Chicago, Illinois, MacroGenics disclosed additional data for the SOPHIA trial. MacroGenics' presentation revealed to the public that the Company had conducted its PFS and overall survival ("OS") analyses in October 2018, and that the OS analyses for the SOPHIA trial did not reflect encouraging post-treatment survival statistics for patients.

On this news, Macrogenics' stock price fell $3.13 per share, or 16.73%, to close at $15.58 per share on June 4, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 561299

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Pomerantz LLP is investigating claims on behalf of investors of GreenLane Holdings, Inc. ("Greenlane" or the "Company") (NASDAQ:GNLN). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980.

The investigation concerns whether Greenlane and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.

[Click here for information about joining the class action]

On or around April 17, 2019, Greenlane conducted its initial public offering ("IPO"), selling approximately 6.45 million shares of common stock priced at $17.00 per share. Then, on June 18, 2019, the San Francisco Board of Supervisors unanimously approved the ban on the sale and distribution of e-cigarette products within the city, and also endorsed a ban on the manufacturing of e-cigarette products on city property.

On this news, Greenlane's stock price fell $2.27 per share, or 17.11%, to close at $11.00 per share on June 19, 2019.

The Pomerantz Firm, with offices in New York, Chicago, Los Angeles, and Paris, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions. Today, more than 80 years later, the Pomerantz Firm continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomerantzlaw.com.

SOURCE: Pomerantz LLP

ReleaseID: 561298

LOS ANGELES, CA / ACCESSWIRE / September 27, 2019 / MjLink.com Inc. a wholly owned subsidiary of Social Life Network, Inc. (OTCQB:WDLF), is pleased to announce Tauriga Sciences, as a Featured Presenter at their MjMicro Conference in Beverly Hills on October 16th at the Sofitel Hotel.

The MjMicro Conference is an invitational forum that unites publicly traded and emerging growth private cannabis companies that are led by seasoned executives, together with high net worth investors and financial analysts.

This one-day cannabis investor conference provides a rare opportunity for attendees to get real-time company updates from each of the presenting companies, and access to an assortment of well-known industry experts that will be speaking throughout the day.

During the conference, Seth Shaw, CEO from Tauriga Sciences will host a featured presentation to update investors and analysts. Tauriga Sciences, Inc (TAUG) operates through the development, distribution, and licensing of proprietary products as well as the evaluation of potential acquisition opportunities. One such opportunity on which the Company has acted, involves the Company having entered into the cannabidiol (or "CBD") infused chewing gum product business. This CBD infused chewing gum product has been branded under the following name: Tauri-Gum™. The Company is currently in production of three distinct flavors of Tauri-Gum™: MINT, BLOOD ORANGE, and POMEGRANATE. Further, the Company continues to identify and evaluate additional potential opportunities to generate revenue, as well as shareholder value, and leverage its resources and expertise to build a diversified and sustainable business model.

In addition, on March 11, 2019, the Company announced the official launch of its E-Commerce site – as part of its Tauri-Gum™ commercialization strategy. This site can be accessed by visiting the following URL address: www.taurigum.com

The Company has established corporate offices in both New York City (USA) and Barcelona (Spain).

To learn more about MjMicro Conference and request an invitation to attend, sponsor or present at the Beverly Hills conference, please visit: https://www.mjmicro.com/attend

About MjLink.com, Inc.

MjLink.com Inc. a wholly owned subsidiary of Social Life Network, Inc. (OTCQB:WDLF), and is a cloud-based cannabis social network and digital media company based in Denver, Colorado. MjLink operates as a multinational cannabis technology and digital media organization with two separate social networks: WeedLife.com, a consumer-to-consumer social network and MjLink.com, a business-to-business social network. MjLink launched its first investor conference in NYC on June 25th, 2019. The MjMicro Conference was so successful that MjLink launched their MjInvest.com investor social network and virtual conference platform in August 2019. MjInvest.com is used by publicly traded companies and emerging private companies to connect, present and provide news flow to accredited online cannabis investors.

For more information about Social Life Network, visit www.SocialNetwork.ai

Disclaimer

This news release may include forward-looking statements within the meaning of section 27A of the United States Securities Act of 1933, as amended, and section 21E of the United States Securities and Exchange Act of 1934, as amended, with respect to achieving corporate objectives, developing additional project interests, the company's analysis of opportunities in the acquisition and development of various project interests and certain other matters. No information in this press release should be construed as any indication whatsoever of the Company's or MjLink's future financial results, revenues or stock price. There are no assurances that the Company will successfully take MjLink.com, Inc public as noted in previous press releases. These statements are made under the "Safe Harbor" provisions of the United States Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements contained herein

CONTACT:
Investor Relations
IR@Social-Life-Network.com
855-933-3277

SOURCE: Social Life Network, Inc.

ReleaseID: 561297

FINANCIAL CONSULTANT APPROVED – CLARIFY: NO CONVERTIBLE DEBT

CORPORATE PROGRESS

FRUITLAND, ID / ACCESSWIRE / September 27, 2019 / XTRA BITCOIN INC (OTC PINK:TCEL)

XTRA's Board has approved adding a new team member to assist in raising expansion capital. Management is working to bring all filings current and improve the financial condition of the company. Among the accomplishments to date are agreements to reduce interest rate on all outstanding debt and the elimination of all convertible debt to protect against dilution of shareholder value.

XTRA hopes to finalize consultant's contract next week. XTRA believes his connections and expertise will help us get the best financing terms that benefit the company and shareholders. Management has been working diligently to bring current all filings and has negotiated for reduced interest rate on outstanding debt and the elimination of all convertible debt note. This has removed dilution risk and strengthens the company's financial position as it pursues expansion financing.

Our discussion may include predictions, estimates or other information that might be considered forward-looking. While these forward-looking statements represent our current judgment on what the future holds, they are subject to risks and uncertainties that could cause actual results to differ materially. You are cautioned not to place undue reliance on these forward-looking statements, which reflect our opinions only as of the date of this presentation. Please keep in mind that we are not obligating ourselves to revise or publicly release the results of any revision to these forward-looking statements in light of new information or future events. You should also review our most recent filings for a more particular discussion of these factors and other risks, particularly under the heading "Risk Factors".

If you would like more information about this topic, please call Paul Knudson at 1-208-707-1008, or email pck710@gmail.com. Twitter: @xtrabitcoin

SOURCE: XTRA Bitcoin Inc.

ReleaseID: 561296

NEW YORK, NY / ACCESSWIRE / September 27, 2019 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. To determine your eligibility and get free access to our shareholder support tools that provide you with case updates, automated loss calculations and claims recovery assistance, please contact the firm via the links below. There will be no cost or obligation to you.

Cardinal Health, Inc. (NYSE:CAH)

Lawsuit on behalf of: investors who purchased March 2, 2015 – May 2, 2018
Lead Plaintiff Deadline : September 30, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/cardinal-health-inc-loss-form?prid=3739&wire=1

According to the filed complaint, during the class period, Cardinal Health, Inc. made materially false and/or misleading statements and/or failed to disclose that: 1) following Cardinal's acquisition of Cordis, the RFID [radio-frequency identification] inventory tracking technology and advanced supply chain solutions that Defendants told investors the Company would to use to improve Cordis's performance were never implemented across Cordis; 2) Cordis's antiquated and ineffective global supply chain was causing operational and inventory problems at Cordis; 3) as a result, Cordis manufactured and accumulated excessive amounts of cardiovascular product inventories, which sat on the shelf and became unsellable and/or expired; 4) the Company materially overstated Cordis's inventory balances; 5) Cordis was not "performing well" and its integration was not "on track," "going incredibly well" or "largely on plan"; and 6) to correct Cordis's deficiencies, the Company would have to make substantial investments in Cordis's IT and supporting infrastructure, thereby incurring significant Selling, General and Administrative Expenses charges beyond the levels internally budgeted or projected by Cardinal and diminishing operating earnings.

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Lawsuit on behalf of: investors who purchased September 6, 2017 – August 19, 2019
Lead Plaintiff Deadline : October 29, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sarepta-therapeutics-inc-loss-form?prid=3739&wire=1

According to the filed complaint, during the class period, Sarepta Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) golodirsen, Sarepta's drug for the treatment of Duchenne muscular dystrophy, posed significant safety risks to patients; (ii) consequently, the New Drug Application package for golodirsen's accelerated approval was unlikely to receive Food and Drug Administration approval; and (iii) as a result, Sarepta's public statements were materially false and misleading at all relevant times.

Sundial Growers Inc. (NASDAQ:SNDL)

Lawsuit on behalf of: investors who purchased pursuant and/or traceable to the registration statement issued in connection with Sundial's August 1, 2019 initial public stock offering.
Lead Plaintiff Deadline : November 25, 2019
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/sundial-growers-inc-loss-form?prid=3739&wire=1

According to the filed complaint, (1) Sundial failed to supply saleable cannabis in line with contractual obligations to Zenabis Global Inc.; (2) due to material quality issues, Zenabis had to return or reject a total of 554 kg of cannabis to Sundial, valued at approximately U.S. $1.9 million (C$2.5 million); and (3) as a result, defendants' statements about Sundial's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.

You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

SOURCE: Levi & Korsinsky, LLP

ReleaseID: 561295